With the validation in the public dataset, CCL21, CCL22, CCL24, CXCL11, CXCL12, CXCL13, GNAI2, and RAC2, enriched in the chemokine signaling pathway in proliferating cells, were determined as the potential biomarkers for treatment of osteosarcoma. Here, CXCL13 is linked to osteosarcoma.